Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Advances in Therapy
Published in: Advances in Therapy 4/2015

Open Access 01-04-2015 | Review

A Biopsychosocial Model for the Management of Patients With Sickle-Cell Disease Transitioning to Adult Medical Care

Authors: Lori E. Crosby, Charles T. Quinn, Karen A. Kalinyak

Published in: Advances in Therapy | Issue 4/2015

Login to get access

Abstract

The lifespan of patients with sickle-cell disease (SCD) continues to increase, and most affected individuals in high-resource countries now live into adulthood. This necessitates a successful transition from pediatric to adult health care. Care for transitioning patients with SCD often falls to primary care providers who may not be fully aware of the many challenges and issues faced by patients and the current management strategies for SCD. In this review, we aim to close the knowledge gap between primary care providers and specialists who treat transitioning patients with SCD. We describe the challenges and issues encountered by these patients, and we propose a biopsychosocial multidisciplinary approach to the management of the identified issues. Examples of this approach, such as transition-focused integrated care models and quality improvement collaboratives, with the potential to improve health outcomes in adulthood are also described.
Appendix
Available only for authorised users
Literature
1.
Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999–2009). Pediatr Blood Cancer. 2013;60:1482–6.CrossRefPubMed
2.
Lanzkron S, Carroll CP, Haywood C Jr. Mortality rates and age at death from sickle cell disease: U.S., 1979–2005. Public Health Rep. 2013;128:110–6.PubMedCentralPubMed
3.
Yanni E, Grosse SD, Yang Q, Olney RS. Trends in pediatric sickle cell disease-related mortality in the United States, 1983–2002. J Pediatr. 2009;154:541–5.CrossRefPubMed
4.
Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512–21.CrossRefPubMed
5.
6.
Wierenga KJ, Hambleton IR, Lewis NA. Survival estimates for patients with homozygous sickle-cell disease in Jamaica: a clinic-based population study. Lancet. 2001;357:680–3.CrossRefPubMed
7.
Vichinsky EP. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol. 1991;28:220–6.PubMed
8.
Streetly A, Latinovic R, Hall K, Henthorn J. Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005–7. J Clin Pathol. 2009;62:26–30.CrossRefPubMedCentralPubMed
9.
Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. N Engl J Med. 1986;314:1593–9.CrossRefPubMed
10.
Adamkiewicz TV, Silk BJ, Howgate J, et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics. 2008;121:562–9.CrossRefPubMed
11.
Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645–51.CrossRefPubMed
12.
Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115:2354–63.CrossRefPubMed
13.
Jordan L, Swerdlow P, Coates TD. Systematic review of transition from adolescent to adult care in patients with sickle cell disease. J Pediatr Hematol Oncol. 2013;35:165–9.CrossRefPubMed
14.
15.
Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I. Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol. 2011;86:116–20.CrossRefPubMed
16.
Lebensburger JD, Bemrich-Stolz CJ, Howard TH. Barriers in transition from pediatrics to adult medicine in sickle cell anemia. J Blood Med. 2012;3:105–12.CrossRefPubMedCentralPubMed
17.
Okumura MJ, Heisler M, Davis MM, Cabana MD, Demonner S, Kerr EA. Comfort of general internists and general pediatricians in providing care for young adults with chronic illnesses of childhood. J Gen Intern Med. 2008;23:1621–7.CrossRefPubMedCentralPubMed
18.
Rosen DS, Blum RW, Britto M, Sawyer SM, Siegel DM. Transition to adult health care for adolescents and young adults with chronic conditions: position paper of the Society for Adolescent Medicine. J Adolesc Health. 2003;33:309–11.CrossRefPubMed
19.
Brown RT, editor. Comprehensive handbook of childhood cancer and sickle cell disease: a biopsychosocial approach. New York: Oxford University Press; 2006.
20.
Nash KB, Telfair J. Sickle cell disease: a biopsychosocial model. In: Livingston I, editor. Handbook of Black American health: the mosaic of conditions, issues, policies, and prospects. Westport: Greenwood Press; 1994. p. 123–39.
21.
Taylor LE, Stotts NA, Humphreys J, Treadwell MJ, Miaskowski C. A biopsychosocial-spiritual model of chronic pain in adults with sickle cell disease. Pain Manag Nurs. 2013;14:287–301.CrossRefPubMed
22.
Ballas SK, Kesen MR, Goldberg MF, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal. 2012;2012:949535.CrossRefPubMedCentralPubMed
23.
Ballas SK, Lieff S, Benjamin LJ, et al. Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol. 2010;85:6–13.CrossRefPubMed
24.
Brousseau DC, Owens PL, Mosso AL, Panepinto JA, Steiner CA. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303:1288–94.CrossRefPubMed
25.
Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353:2769–78.CrossRefPubMed
26.
27.
Knight-Madden JM, Forrester TS, Lewis NA, Greenough A. Asthma in children with sickle cell disease and its association with acute chest syndrome. Thorax. 2005;60:206–10.CrossRefPubMedCentralPubMed
28.
Sharpe CC, Thein SL. Sickle cell nephropathy—a practical approach. Br J Haematol. 2011;155:287–97.CrossRefPubMed
29.
Rogers ZR. Priapism in sickle cell disease. Hematol Oncol Clin N Am. 2005;19:917–28 (viii).CrossRef
30.
Porter JB, Evangeli M. Challenges of adherence and persistence with iron chelation therapy. Int J Hematol. 2011;94:453–60.CrossRefPubMed
31.
Chen E, Cole SW, Kato PM. A review of empirically supported psychosocial interventions for pain and adherence outcomes in sickle cell disease. J Pediatr Psychol. 2004;29:197–209.CrossRefPubMed
32.
Wang WC. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Curr Opin Hematol. 2007;14:191–7.CrossRefPubMed
33.
34.
Aygun B, Wruck LM, Schultz WH, et al. Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. Am J Hematol. 2012;87:428–30.CrossRefPubMed
35.
36.
Howard J, Woodhead T, Musumadi L, Martell A, Inusa BP. Moving young people with sickle cell disease from paediatric to adult services. Br J Hosp Med (Lond). 2010;71:310–4.CrossRef
37.
Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998;19:110–29.CrossRefPubMed
38.
Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–94.PubMed
39.
DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E, Kirkham FJ. Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 2012;119:4587–96.CrossRefPubMedCentralPubMed
40.
Pegelow CH, Macklin EA, Moser FG, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99:3014–8.CrossRefPubMed
41.
Vichinsky EP, Neumayr LD, Gold JI, et al. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010;303:1823–31.CrossRefPubMedCentralPubMed
42.
Kugler S, Anderson B, Cross D, et al. Abnormal cranial magnetic resonance imaging scans in sickle-cell disease. Neurological correlates and clinical implications. Arch Neurol. 1993;50:629–35.CrossRefPubMed
43.
44.
DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:699–710.CrossRefPubMedCentralPubMed
45.
Halfon N, Hochstein M. Life course health development: an integrated framework for developing health, policy, and research. Milbank Q. 2002;80:433–79 (iii).CrossRefPubMedCentralPubMed
46.
King AA, Strouse JJ, Rodeghier MJ, et al. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014;89:162–7.CrossRefPubMedCentralPubMed
47.
DeBaun MR, Sarnaik SA, Rodeghier MJ, et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood. 2012;119:3684–90.CrossRefPubMedCentralPubMed
48.
Dale JC, Cochran CJ, Roy L, Jernigan E, Buchanan GR. Health-related quality of life in children and adolescents with sickle cell disease. J Pediatr Health Care. 2011;25:208–15.CrossRefPubMedCentralPubMed
49.
Telfair J, Myers J, Drezner S. Transfer as a component of the transition of adolescents with sickle cell disease to adult care: adolescent, adult, and parent perspectives. J Adolesc Health. 1994;15:558–65.CrossRefPubMed
50.
McPherson M, Thaniel L, Minniti CP. Transition of patients with sickle cell disease from pediatric to adult care: assessing patient readiness. Pediatr Blood Cancer. 2009;52:838–41.CrossRefPubMed
51.
Wojciechowski EA, Hurtig A, Dorn L. A natural history study of adolescents and young adults with sickle cell disease as they transfer to adult care: a need for case management services. J Pediatr Nurs. 2002;17:18–27.CrossRefPubMed
52.
Wilkie DJ, Johnson B, Mack AK, Labotka R, Molokie RE. Sickle cell disease: an opportunity for palliative care across the life span. Nurs Clin N Am. 2010;45:375–97.CrossRef
53.
Hauser ES, Dorn L. Transitioning adolescents with sickle cell disease to adult-centered care. Pediatr Nurs. 1999;25:479–88.PubMed
54.
Eccleston C, Palermo TM, de C Williams AC, et al. Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database Syst Rev. 2012;12:CD003968.PubMedCentralPubMed
55.
56.
57.
Strouse JJ, Jordan LC, Lanzkron S, Casella JF. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol. 2009;84:548–52.CrossRefPubMedCentralPubMed
58.
Liburd LC, Sniezek JE. Changing times: new possibilities for community health and well-being. Prev Chronic Dis. 2007;4:A73.PubMedCentralPubMed
59.
King AA, DeBaun MR, White DA. Need for cognitive rehabilitation for children with sickle cell disease and strokes. Expert Rev Neurother. 2008;8:291–6.CrossRefPubMed
60.
Bediako SM. Predictors of employment status among African Americans with sickle cell disease. J Health Care Poor Underserved. 2010;21:1124–37.PubMed
61.
62.
American Academy of Pediatrics. Health supervision for children with sickle cell disease. Pediatrics. 2002;109:526–35.CrossRef
63.
Okumura MJ, Kerr EA, Cabana MD, Davis MM, Demonner S, Heisler M. Physician views on barriers to primary care for young adults with childhood-onset chronic disease. Pediatrics. 2010;125:e748–54.CrossRefPubMed
64.
65.
National Institutes of Health, National Heart, Lung, and Blood Institute. The management of sickle cell disease. NIH Publication No. 02-2117; 2002.
66.
Doulton DM. From cradle to commencement: transitioning pediatric sickle cell disease patients to adult providers. J Pediatr Oncol Nurs. 2010;27:119–23.CrossRefPubMed
67.
68.
American Academy of Pediatrics, American Academy of Family Physicians, and American College of Physicians, Transitions Clinical Report Authoring Group. Supporting the health care transition from adolescence to adulthood in the medical home. Pediatrics. 2011;128:182–200.CrossRef
69.
Grosse SD, Schechter MS, Kulkarni R, Lloyd-Puryear MA, Strickland B, Trevathan E. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123:407–12.CrossRefPubMed
70.
Metadata
Title
A Biopsychosocial Model for the Management of Patients With Sickle-Cell Disease Transitioning to Adult Medical Care
Authors
Lori E. Crosby
Charles T. Quinn
Karen A. Kalinyak
Publication date
01-04-2015
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 4/2015
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-015-0197-1

Other articles of this Issue 4/2015

Advances in Therapy 4/2015 Go to the issue

Erratum

Erratum to: Management of Bone Disease in Gaucher Disease Type 1: Clinical Practice

Review

Asthma Control: The Right Inhaler for the Right Patient

Original Research

Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study

Original Research

Patient Reported Burden of Asthma on Resource Use and Productivity Across 11 Countries in Europe

Erratum

Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users

Original Research

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits